These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

509 related items for PubMed ID: 8665590

  • 1. Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts.
    Gabrilovich DI, Ciernik IF, Carbone DP.
    Cell Immunol; 1996 May 25; 170(1):101-10. PubMed ID: 8665590
    [Abstract] [Full Text] [Related]

  • 2. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors.
    Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP.
    Cell Immunol; 1996 May 25; 170(1):111-9. PubMed ID: 8665591
    [Abstract] [Full Text] [Related]

  • 3. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI, Stanziale SF, Lunin SD, Zaremba S, Schlom J.
    Eur J Immunol; 1996 Feb 25; 26(2):435-43. PubMed ID: 8617315
    [Abstract] [Full Text] [Related]

  • 4. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
    Cao X, Zhang W, He L, Xie Z, Ma S, Tao Q, Yu Y, Hamada H, Wang J.
    J Immunol; 1998 Dec 01; 161(11):6238-44. PubMed ID: 9834111
    [Abstract] [Full Text] [Related]

  • 5. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells.
    Toes RE, van der Voort EI, Schoenberger SP, Drijfhout JW, van Bloois L, Storm G, Kast WM, Offringa R, Melief CJ.
    J Immunol; 1998 May 01; 160(9):4449-56. PubMed ID: 9574550
    [Abstract] [Full Text] [Related]

  • 6. [Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].
    Zhang W, He L, Cao X.
    Zhonghua Yi Xue Za Zhi; 1999 Mar 01; 79(3):170-3. PubMed ID: 11601032
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow.
    Yang S, Darrow TL, Vervaert CE, Seigler HF.
    Cell Immunol; 1997 Jul 10; 179(1):84-95. PubMed ID: 9259775
    [Abstract] [Full Text] [Related]

  • 8. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity.
    Liu Y, Huang H, Chen Z, Zong L, Xiang J.
    J Gene Med; 2003 Aug 10; 5(8):668-80. PubMed ID: 12898636
    [Abstract] [Full Text] [Related]

  • 9. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen.
    Saha A, Chatterjee SK, Foon KA, Celis E, Bhattacharya-Chatterjee M.
    Cancer Res; 2007 Mar 15; 67(6):2881-92. PubMed ID: 17363612
    [Abstract] [Full Text] [Related]

  • 10. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
    Yang B, He Y, Sun DL, Zou Y, Qin XH, Huang BH.
    Zhonghua Yi Xue Za Zhi; 2008 Jul 22; 88(28):1956-60. PubMed ID: 19062734
    [Abstract] [Full Text] [Related]

  • 11. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
    Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP.
    Clin Cancer Res; 1999 Oct 22; 5(10):2963-70. PubMed ID: 10537366
    [Abstract] [Full Text] [Related]

  • 12. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T, Iwahashi M, Nakamura M, Matsuda K, Naka T, Nakamori M, Ueda K, Ishida K, Yamaue H.
    Int J Oncol; 2006 Apr 22; 28(4):947-53. PubMed ID: 16525645
    [Abstract] [Full Text] [Related]

  • 13. Induction of antitumor immunity using bone marrow-generated dendritic cells.
    Porgador A, Snyder D, Gilboa E.
    J Immunol; 1996 Apr 15; 156(8):2918-26. PubMed ID: 8609412
    [Abstract] [Full Text] [Related]

  • 14. Delivery of interferon-alpha transfected dendritic cells into central nervous system tumors enhances the antitumor efficacy of peripheral peptide-based vaccines.
    Okada H, Tsugawa T, Sato H, Kuwashima N, Gambotto A, Okada K, Dusak JE, Fellows-Mayle WK, Papworth GD, Watkins SC, Chambers WH, Potter DM, Storkus WJ, Pollack IF.
    Cancer Res; 2004 Aug 15; 64(16):5830-8. PubMed ID: 15313927
    [Abstract] [Full Text] [Related]

  • 15. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells.
    Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA.
    Cancer Res; 1993 Jul 15; 53(14):3257-61. PubMed ID: 7686815
    [Abstract] [Full Text] [Related]

  • 16. [Anti-tumor immune response of dendritic cells transfected with wild-type p53 gene].
    Liu HJ, Xin JB, Li ZY, Xiong XZ, Tao XN, Hu Y.
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Dec 15; 31(12):902-7. PubMed ID: 19134406
    [Abstract] [Full Text] [Related]

  • 17. Definition of an immunogenic region within the ovarian tumor antigen stratum corneum chymotryptic enzyme.
    Bondurant KL, Crew MD, Santin AD, O'Brien TJ, Cannon MJ.
    Clin Cancer Res; 2005 May 01; 11(9):3446-54. PubMed ID: 15867247
    [Abstract] [Full Text] [Related]

  • 18. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J, Saffold S, Cao X, Krauss J, Chen W.
    J Immunol; 1998 Nov 15; 161(10):5516-24. PubMed ID: 9820528
    [Abstract] [Full Text] [Related]

  • 19. Vaccination with dendritic cells pulsed in vitro with tumor antigen conjugated to cholera toxin efficiently induces specific tumoricidal CD8+ cytotoxic lymphocytes dependent on cyclic AMP activation of dendritic cells.
    Sun JB, Eriksson K, Li BL, Lindblad M, Azem J, Holmgren J.
    Clin Immunol; 2004 Jul 15; 112(1):35-44. PubMed ID: 15207780
    [Abstract] [Full Text] [Related]

  • 20. Dendritic cells pulsed with an anti-idiotype antibody mimicking carcinoembryonic antigen (CEA) can reverse immunological tolerance to CEA and induce antitumor immunity in CEA transgenic mice.
    Saha A, Chatterjee SK, Foon KA, Primus FJ, Sreedharan S, Mohanty K, Bhattacharya-Chatterjee M.
    Cancer Res; 2004 Jul 15; 64(14):4995-5003. PubMed ID: 15256474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.